AL
At a glance
Registered since
2024
Senate LDA system
Clients
4
last 3 years
Filings
10
3 agencies contacted
Activity
filings by quarter
Works on
Specific issues
H.R. 5391/S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; Access and reimbursement of Part B Drugs in Medicare; Continued expansion of Telehealth services including in H.R. 3875/S. 3967, Expanded Telehealth Access Act and Telehealth Modernization Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act (PATIENT Act) of 2023; H.R. 4822, Health Care Price Transparency Act of 2023; Support for site neutrality policies in H.R. 5378, Lower Costs, More Transparency Act; Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022; Issues related to MACRA Reform including H.R. 2474, Strengthening Medicare for Patients and Providers Act; Support the passage of H.R. 5526/S. 3458, the Seniors' Access to Critical Medications Act; H.R. 6683, Preserving Seniors Access to Physicians Act of 2023; Issues related to prior authorization in H.R. 8702/S. 4518, Improving Seniors Timely Access to Care Act of 2024
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)
Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860/S. 5018, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023
Telehealth extension; Issues related to site neutral payments; Issues related to prior authorization in Medicare Advantage; Issues related to physician payment reform; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 5526/S.3458, Seniors Access to Critical Medications Act of 2023; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3284, Providers and Payers COMPETE Act; S. 2764/H.R. 5391, Protecting Patient Access to Cancer and Complex Therapies Act of 2023; H.R. 5378, The Lower Costs, More Transparency Act
Telehealth extension; Issues related to site neutral payments; Issues related to healthcare transparency and consolidation; Issues related to prior authorization in Medicare Advantage; Issues related to physician payment reform; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 5526/S.3458, Seniors Access to Critical Medications Act of 2023; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3284, Providers and Payers COMPETE Act; S. 2764 / H.R. 5391, Protecting Patient Access to Cancer and Complex Therapies Act of 2023; H.R. 5378, The Lower Costs, More Transparency Act
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)
Clients
Filing history
LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA)
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC.
KIDNEY CARE PARTNERS
FRESENIUS MEDICAL CARE NORTH AMERICA
KIDNEY CARE PARTNERS
FRESENIUS MEDICAL CARE NORTH AMERICA
LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA)
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC.
LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA)
KIDNEY CARE PARTNERS